Cullinan Oncology Inc Stock Price, News & Analysis

Cullinan Oncology (CGEM) has secured an exclusive license from Harbour BioMed for the U.S. development of CLN-418/HBM7008, a bispecific immune activator currently in Phase 1 clinical trials. The deal includes a $25 million upfront payment to Harbour BioMed, with potential milestone payments totaling up to $563 million, plus tiered royalties on U.S. sales. CLN-418 targets B7H4 and 4-1BB, aiming to enhance cancer treatment efficacy, especially in solid tumors with low expression of PD-L1. Cullinan expects to expand its clinical pipeline to six assets by the end of 2023, positioning itself at the forefront of the bispecific antibody space.

On February 2, 2023, Cullinan Oncology (Nasdaq: CGEM) announced that President and CEO Nadim Ahmed will participate in two major conferences this February. He will engage in a fireside chat at Guggenheim’s 5th Annual Oncology Conference on February 8, 2023, at 1:00 p.m. EST, and at the SVB Securities Global Biopharma Conference on February 15, 2023, at 10:40 a.m. EST. Live webcasts of these sessions will be available on the Company's investor relations website. Investors can also arrange one-on-one meetings with management during these events.

Cullinan Oncology aims to innovate cancer therapies across various modalities and partners with academic and industry leaders to enhance cancer treatment.

Cullinan Oncology, Inc. (Nasdaq: CGEM) announced the granting of stock options to three new employees, totaling 56,000 shares. The options, part of a Nasdaq inducement plan, have an exercise price of $11.58, matching the stock's closing price on February 1, 2023. Each option features a ten-year term with a vesting schedule: 25% vesting after the first year, followed by equal monthly installments over the next three years, contingent on continued employment. This move aims to attract talent and incentivize long-term commitment among staff as Cullinan focuses on innovative cancer therapies.

Cullinan Oncology, Inc. (Nasdaq: CGEM) announced that the FDA has cleared its IND application for CLN-978, a bispecific antibody targeting CD19/CD3. This construct is designed for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL). The Phase 1 trial will assess the safety and efficacy of CLN-978, which features a novel design for improved potency and subcutaneous delivery. This marks Cullinan's fourth clinical-stage asset and underscores its dedication to enhancing cancer treatment standards. Furthermore, the IND submission for CLN-617 is anticipated in the first half of 2023.

Cullinan Oncology, a biopharmaceutical focused on cancer therapies, announced the grant of stock options for 86,000 shares to three new employees outside its 2021 Incentive Plan. The options were awarded on December 1, 2022, at an exercise price of $12.26, matching the stock's closing price on that day. Each option will vest over four years, beginning with 25% on the first anniversary. These actions comply with Nasdaq Listing Rule 5635(c)(4), designed to facilitate talent acquisition in line with their growth strategy.

Cullinan Oncology (CGEM) has initiated a pivotal study for zipalertinib in patients with EGFR exon 20 non-small cell lung cancer. The company has increased its ownership in MICA subsidiary from 54% to 92%. Initial clinical data updates for the CLN-049 and CLN-619 programs are expected in mid-2023. As of September 30, 2022, Cullinan has approximately $607 million in cash and investments. The third quarter net loss was $24.9 million, with R&D expenses decreasing to $19.7 million. Leadership changes include the appointment of Jacquelyn Sumer as Chief Legal Officer.

Cullinan Oncology (NASDAQ: CGEM) announced the appointment of Dr. David P. Ryan to its Board of Directors, effective immediately. Dr. Ryan has over 20 years of experience in oncology, currently serving as Clinical Director at Massachusetts General Hospital Cancer Center. He replaces Dr. Ansbert Gadicke, a founding member, who has been instrumental in the company’s transition to a public entity since 2016. Dr. Ryan's expertise in clinical research and gastrointestinal malignancies is expected to support Cullinan's diverse oncology pipeline.

Cullinan Oncology, Inc. (Nasdaq: CGEM) announced the granting of stock options for 147,000 shares to four new employees on November 1, 2022. The options, issued outside of its 2021 Stock Option and Incentive Plan, feature an exercise price of $13.26, matching the company's closing stock price on the grant date. Each option vests over four years, with the first installment vesting after one year. This grant follows Nasdaq Listing Rule 5635(c)(4), aimed at incentivizing new hires as Cullinan continues its focus on developing targeted oncology therapies.

Cullinan Oncology (Nasdaq: CGEM) has announced its participation in several upcoming investor conferences. CFO Jeff Trigilio will present at the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022, at 11:35 a.m. EST. CEO Nadim Ahmed will speak at the Stifel 2022 Healthcare Conference in New York on November 16, 2022, at 4:45 p.m. EST, and will also participate in a virtual fireside chat at the Evercore ISI 5th Annual HEALTHCONx conference on December 1, 2022, at 8:25 a.m. EST. Webcasts of these events will be available on the company's investor relations website.